ARTICLE | Company News
Dynavax submits Heplisav BLA
April 27, 2012 1:02 AM UTC
Dynavax Technologies Corp. (NASDAQ:DVAX) submitted a BLA to FDA for Heplisav to prevent HBV infection caused by all known subtypes in adults 18-70 years of age. Dynavax requested Priority Review for t...